INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
499.55 EUR
-4.35 (-0.86%)
Taking everything into account, IUI1 scores 6 out of 10 in our fundamental rating. IUI1 was compared to 68 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IUI1 a very profitable company, without any liquidiy or solvency issues. IUI1 is valued quite expensive, but it does show an excellent growth. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
IUI1 had positive earnings in the past year.
In the past year IUI1 had a positive cash flow from operations.
IUI1 had positive earnings in each of the past 5 years.
In the past 5 years IUI1 always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.19%, IUI1 belongs to the top of the industry, outperforming 92.65% of the companies in the same industry.
IUI1 has a better Return On Equity (16.12%) than 83.82% of its industry peers.
IUI1 has a Return On Invested Capital of 11.69%. This is amongst the best in the industry. IUI1 outperforms 82.35% of its industry peers.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 9.73%.
The last Return On Invested Capital (11.69%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
IUI1 has a better Profit Margin (28.58%) than 97.06% of its industry peers.
In the last couple of years the Profit Margin of IUI1 has declined.
With an excellent Operating Margin value of 29.44%, IUI1 belongs to the best of the industry, outperforming 98.53% of the companies in the same industry.
IUI1's Operating Margin has declined in the last couple of years.
IUI1's Gross Margin of 66.38% is fine compared to the rest of the industry. IUI1 outperforms 75.00% of its industry peers.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
Compared to 5 years ago, IUI1 has more shares outstanding
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.18
WACC9.94%
2.3 Liquidity
IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IUI1 (4.97) is better than 95.59% of its industry peers.
A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
The Quick ratio of IUI1 (4.20) is better than 95.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.18%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
The Earnings Per Share is expected to grow by 15.67% on average over the next years. This is quite good.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 67.51, IUI1 can be considered very expensive at the moment.
60.29% of the companies in the same industry are cheaper than IUI1, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.19. IUI1 is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 58.61, IUI1 can be considered very expensive at the moment.
IUI1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 72.06% of the companies in the same industry.
IUI1 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.51 | ||
| Fwd PE | 58.61 |
4.2 Price Multiples
67.65% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 90.77 | ||
| EV/EBITDA | 57.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)3.35
PEG (5Y)5.88
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/9/2026, 7:00:00 PM)
499.55
-4.35 (-0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap177.09B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target523.6 (4.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)-0.15%
PT rev (3m)2.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.15%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.51 | ||
| Fwd PE | 58.61 | ||
| P/S | 21.45 | ||
| P/FCF | 90.77 | ||
| P/OCF | 69.64 | ||
| P/B | 12.1 | ||
| P/tB | 12.35 | ||
| EV/EBITDA | 57.33 |
EPS(TTM)7.4
EY1.48%
EPS(NY)8.52
Fwd EY1.71%
FCF(TTM)5.5
FCFY1.1%
OCF(TTM)7.17
OCFY1.44%
SpS23.29
BVpS41.29
TBVpS40.45
PEG (NY)3.35
PEG (5Y)5.88
Graham Number82.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC9.94%
ROIC/WACC1.18
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.